Is there any association between cognitive deficits and immune markers in Acute and Transient psychotic disorders? A pilot study.

[1]  P. McGuire,et al.  Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment , 2023, Molecular Psychiatry.

[2]  P. Plichta,et al.  Serum Inflammatory Markers and Their Associations with the Integrity of the Cingulum Bundle in Schizophrenia, from Prodromal Stages to Chronic Psychosis , 2022, Journal of clinical medicine.

[3]  D. Basu,et al.  Immune‐mediated inflammatory markers in acute and transient psychotic disorders—comparison with schizophrenia: An exploratory comparative study , 2022, Early intervention in psychiatry.

[4]  M. Cella,et al.  Cognitive impairment in people with schizophrenia: an umbrella review , 2022, European Archives of Psychiatry and Clinical Neuroscience.

[5]  M. Leboyer,et al.  The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis , 2022, Molecular Psychiatry.

[6]  L. Pantoni,et al.  Translations and cultural adaptations of the Montreal Cognitive Assessment: a systematic and qualitative review , 2021, Neurological Sciences.

[7]  Swapnajeet Sahoo,et al.  Acute and Transient Psychotic Disorders: Newer Understanding , 2019, Current Psychiatry Reports.

[8]  Vidushi Sharma,et al.  Validity and reliability of hindi translated version of Montreal cognitive assessment in older adults. , 2019, Asian journal of psychiatry.

[9]  Ni Fan,et al.  Changes in serum TNF-α, IL-18, and IL-6 concentrations in patients with chronic schizophrenia at admission and at discharge. , 2019, Comprehensive psychiatry.

[10]  D. Antoniadis,et al.  Cytokines, cortisol and IGF-1 in first episode psychosis and ultra high risk males. Evidence for TNF-α, IFN-γ, ΤNF-β, IL-4 deviation. , 2017, Asian journal of psychiatry.

[11]  V. Negi,et al.  An exploratory study of immune markers in acute and transient psychosis. , 2017, Asian journal of psychiatry.

[12]  D. Basu,et al.  Auditory P300 event related potentials in acute and transient psychosis-Comparison with schizophrenia. , 2016, Asian journal of psychiatry.

[13]  E. Vasar,et al.  Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index , 2015, Schizophrenia Research.

[14]  R. Murray,et al.  Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis , 2015, Schizophrenia bulletin.

[15]  R. Alizadeh-Navaei,et al.  Serum TNF-α, IL-10 and IL-2 in schizophrenic patients before and after treatment with risperidone and clozapine. , 2014, Iranian journal of immunology : IJI.

[16]  J. Salgado,et al.  Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review , 2014, Current neuropharmacology.

[17]  S. Farooq.  Is acute and transient psychotic disorder (ATPD) mini schizophrenia? The evidence from phenomenology and epidemiology. , 2012, Psychiatria Danubina.

[18]  Christos Pantelis,et al.  Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study , 2009, British Journal of Psychiatry.

[19]  S. Faraone,et al.  Neurocognition in first-episode schizophrenia: a meta-analytic review. , 2009, Neuropsychology.

[20]  Benedicto Crespo-Facorro,et al.  Cognitive dimensions in first-episode schizophrenia spectrum disorders. , 2007, Journal of psychiatric research.

[21]  Philip D. Harvey.  Is cognitive impairment in schizophrenia multidimensional?: implications for assessment and treatment. , 2007, Psychiatry (Edgmont (Pa. : Township)).

[22]  Philip D. Harvey,et al.  Cognitive deficits and functional outcome in schizophrenia , 2006, Neuropsychiatric disease and treatment.

[23]  C. Stefanis,et al.  Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients , 2001, Schizophrenia Research.

[24]  T. Mosmann,et al.  The expanding universe of T-cell subsets: Th1, Th2 and more. , 1996, Immunology today.

[25]  B. Rabin,et al.  Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. , 1995, Archives of general psychiatry.

[26]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .